<DOC>
	<DOCNO>NCT00548548</DOCNO>
	<brief_summary>This study compare treatment bevacizumab combination capecitabine cisplatin versus placebo combination capecitabine cisplatin , first-line therapy patient locally advance metastatic gastric cancer receive prior chemotherapy advance metastatic disease .</brief_summary>
	<brief_title>A Study Bevacizumab Combination With Capecitabine Cisplatin First-line Therapy Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description>This 2 arm , randomize , double-blind , multicenter phase III study . Patients randomize ( 1:1 ) capecitabine/cisplatin plus bevacizumab capecitabine/cisplatin plus placebo . This event-driven trial primary analysis plan approximately 517 death observe . After primary analysis , study remain open patient continue study treatment progressive disease earlier investigator 's discretion . After discontinuation last patient , study end globally .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Written inform consent obtain prior study specific procedure . Age ≥ 18 year . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . Life expectancy least 3 month . Able comply protocol . Histologically confirm adenocarcinoma stomach gastrooesophageal junction inoperable , locally advanced , metastatic disease , amenable curative therapy . Measurable disease nonmeasurable evaluable disease , accord Response Evaluation Criteria Solid Tumours ( RECIST ) . Patient receive anticoagulant medication must International normalized ratio ( INR ) ≤ 1.5 activate partial thromboplastin time ( aPTT ) ≤ 1.5 x Upper Limit Normal ( ULN ) within 7 day prior randomisation . Previous chemotherapy locally advance metastatic gastric cancer . Patients may receive prior neoadjuvant adjuvant chemotherapy long complete least 6 month prior randomisation . Previous platinum antiangiogenic therapy ( ie , antivascular endothelial growth factor [ VEGF ] VEGF receptor tyrosine kinase inhibitor , etc. ) . Patients locally advanced disease candidate curative therapy ( include operation and/or chemotherapy and/or radiotherapy ) . Radiotherapy within 28 day randomisation . Major surgical procedure , open biopsy significant traumatic injury within 28 day prior randomisation , anticipation need major surgery course study treatment ( plan elective surgery ) . Minor surgical procedure within 2 day prior randomisation . Evidence central nervous system ( CNS ) metastasis baseline . History evidence upon physical/neurological examination CNS disease unrelated cancer unless adequately treat standard medical therapy , eg , uncontrolled seizure . History another malignancy could affect compliance protocol interpretation result . Inadequate bone marrow function . Inadequate liver function . Inadequate renal function . Uncontrolled hypertension clinically significant ( ie , active ) cardiovascular disease . Active infection require intravenous antibiotic randomisation . History evidence inherit bleed diathesis coagulopathy risk bleeding . Serious nonhealing wound , peptic ulcer , ( incompletely heal ) bone fracture . Active gastrointestinal bleeding . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month randomisation . Neuropathy ( eg , impairment hear balance ) ≥ grade II accord Common Terminology Criteria Adverse Events ( CTCAE ) v3.0 . Chronic daily treatment aspirin clopidogrel . Chronic daily treatment oral corticosteroid ; inhale steroid short course oral steroid antiemesis appetite stimulant allow . Known hypersensitivity study drug excipients Chinese hamster ovary cell product recombinant human humanise antibody . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency . Evidence disease , metabolic psychological dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug , may affect patient compliance study , place patient high risk treatment complication . Known acute chronicactive infection hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . Pregnant lactating female . Women childbearing potential use effective nonhormonal ( intrauterine contraceptive device , barrier method contraception conjunction spermicidal jelly , surgically sterile ) mean contraception . Sexually active men unwilling practice contraception study . Current recent ( within 28 day prior randomisation ) treatment another investigational drug participation another investigational study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Avastin</keyword>
	<keyword>Metastatic Adenocarcinoma</keyword>
	<keyword>AVAGAST</keyword>
</DOC>